Sentences with phrase «immunotherapy combination»
"Immunotherapy combination" refers to a medical treatment approach where multiple immunotherapies are used together to help the immune system fight against diseases like cancer. This combination can increase effectiveness and provide better results than using a single immunotherapy drug alone. Full definition
«Immune checkpoint inhibitors, including PD - 1 and PD - L1 inhibitors, have provided meaningful clinical benefits for patients with cancer; however, novel immunotherapy combination treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
aacr.org
«New immunotherapy combination effective at killing cancer cells: Familiar drugs used in new way deliver promising results.»
In September of 2015, the one - two punch that saved my life became the first immunotherapy combination treatment to gain FDA approval.
«Immunotherapy combination promising for untreated patients with advanced melanoma.»
Phase 1b study of a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma.
Hollings Cancer Center researchers publish results from a novel immunotherapy combination for non-small cell lung cancer in The Lancet Oncology.
Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors.
«Immunotherapy combination safe and 62 percent effective in metastatic melanoma patients.»
She has identified novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic immunotherapy combinations.
Despite high rates of toxicity, a first - line tyrosine kinase inhibitor / immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.
Jun joined the Cancer Research Institute in January 2017 as a senior research analyst in the Institute's Clinical Accelerator program, where he is using his scientific training to help accelerate the translation of new cancer immunotherapy combinations from labs to the clinic.
They suggest allocating greater resources to research focused on immune checkpoint therapies and targeted / immunotherapy combination therapies with «curative potential.»
The Anna - Maria Kellen Clinical Accelerator, the clinical arm of Cancer Research Institute (CRI), is a unique academia - nonprofit - industry collaboration model that serves as an «incubator» to accelerate clinical trials of promising new immunotherapy combinations.
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
Turnstone also is developing additional oncolytic virus strategies and immunotherapy combination treatments.
His lab is one of three in the world looking at this immunotherapy combination.
Xconomy rounded up some of the other headlines, including advances in targeted cancer medicines, cell therapies, immunotherapy combinations and more.
Results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
Hollings Cancer researchers publish results, in The Lancet Oncology about a novel immunotherapy combination that shows promise for lung cancer patients.
CRI's clinical program, The Anna - Maria Kellen Clinical Accelerator, is a unique academia - industry collaboration model that serves as an «incubator» for promising new immunotherapy combinations.